Tissue-specific imaging is a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage

American Journal of Neuroradiology

Volumn 30, Issue 7, 2009, Pages 1394-1401

  Riva, M ^a   Ikonomidou, V N ^a,b   Ostuni, J J ^a   Van Gelderen, P ^b   Auh, S ^a   Ohayon, J M ^a   Tovar Moll, F ^a   Richert, N D ^a   Duyn, J H ^b   Bagnato, Francesca ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; STEROID;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN REGION; BRAIN TISSUE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS CALLOSUM; FEMALE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 68549107850     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1573     Document Type: Article

References (43)

1. Grossman RI, Gonzalez-Scarano F, Atlas SW, et al. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;161:721-725 (Pubitemid 17200424)
2. Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640-646 (Pubitemid 36246083)
3. Gupta S, Solomon JM, Tasciyan TA, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005;11:658-668 (Pubitemid 41685136)
4. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555
5. Van Walderveen MA, Lycklama A, Nijeholt GJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001;58:76-81 (Pubitemid 32053210)
6. Bagnato F, Evangelou I, Gaindh D, et al. The role of interferon beta in T1- hypointese black holes in multiple sclerosis. Expert Opin Biol Ther 2007;7:1079-1091
7. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-754 (Pubitemid 29518136)
8. Ciccarelli O, Giugni E, Paolillo A, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999;6:455-459 (Pubitemid 29371143)
9. Filippi M, Rovaris M, Rocca MA, et al. Glatimerar acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001;57:731-733
10. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001;57:2185-2190 (Pubitemid 34016449)
11. Bagnato F, Jeffries N, Richert N, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126:1782-1789 (Pubitemid 36917337)
12. Freitag P, Mueller B, Radue EW, et al. Individual changes of chronic black holes. Mult Scler 2001;7 S1, P094
13. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476 (Pubitemid 26422538)
14. Barkhof F, van Waesberghe JH, Filippi M, et al. European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis. T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001;124:1396-1402
15. Sailer M, Losseff NA, Wang L, et al. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. Eur J Neurol 2001;8:37-42 (Pubitemid 32154572)
16. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-245 (Pubitemid 34596884)
17. Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739-752
18. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684-1690
19. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288 (Pubitemid 28240340)
20. Bitsch A, Kuhlmann T, Stadelmann C, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001;49:793-796 (Pubitemid 32530247)
21. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis. Magnetic resonance imaging appearance. Arch Neurol 2003;60:1073-1081 (Pubitemid 36975794)
22. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793 (Pubitemid 27481551)
23. Lassmann H. The pathological substrate of magnetic resonance alterations in multiple sclerosis. Neuroimag Clin N Am 2008;18:563-576
24. Ikonomidou VN, van Gelderen P, de Zwart JA, et al. Optimizing brain tissue contrast with EPI: a simulated annealing approach. Magn Res Med 2005;54:373-385
25. Bottomley PA, Foster TH, Argensinger RE, et al. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHZ: dependence on tissue type, NMR frequency, temperature, species, excision and age. Med Phys 1984;11:425-448
26. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231 (Pubitemid 13158528)
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
28. Fischer JS, Rudick RA, Cutter GR, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244-250
29. Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001;7:49-59
30. Cohen MS, DuBois RM, Zeineh MM. Rapid and effective correction of RF inhomogeneity for high field magnetic resonance imaging. Hum Brain Mapp 2000;10:204-211
31. Filippi M, Gawne-Cain ML, Gasperini C, et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-244 (Pubitemid 28106048)
32. Richert ND, Ostuni JL, Bash CN, et al. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 1998;19:1705-1713
33. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489
34. Bagnato F, Butman JA, Mora CA, et al. Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol 2005;11:525-534 (Pubitemid 43123771)
35. Redpath TW, Smith FW. Technical note: use of a double inversion recovery pulse sequence to image selectively grey or white brain matter. Br J Radiol 1994;67:1258-1263
36. Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 2007;28:54-59 (Pubitemid 46147534)
37. Moraal B, Roosendaal SD, Pouwels PJ, et al. Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol 2008;18:2311-2320
38. Madelin G, Oesingmann N, Inglese M. Double inversion recovery MRI with fat suppression at 7 Tesla: initial experience. J Neuroimaging 2008 Nov 6. [Epub ahead of print]
39. van Waesberghe JHTM, Kamphorst W, De Groot CJA, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-754 (Pubitemid 29518136)
40. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407-415 (Pubitemid 39166560)
41. Giugni E, Pozzilli C, Bastianello S, et al. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 1997;3:221-225 (Pubitemid 27478585)
42. Zivadinov R, Stosic M, Cox JL, et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 2008;255:61-74 (Pubitemid 351341874)
43. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158-170 (Pubitemid 43107851)